What are mesalamine delayed-release tablets (1.2 g) used for?
Mesalamine delayed-release tablets (often sold as 1.2 g strengths) are used to treat inflammatory bowel disease, particularly ulcerative colitis, including maintenance therapy to help keep symptoms under control. The delayed-release design helps deliver mesalamine to the intestine rather than the stomach.
What does “1.2 g” mean for dosing?
A common tablet strength is 1.2 g per tablet. Typical regimens are written as grams per day (for example, multiple tablets to reach a daily total). Exact dosing depends on whether it’s for induction (to bring symptoms under control) versus maintenance, and on the patient’s condition and prescriber instructions.
If you’re trying to confirm a specific product, the “1.2 g” tablet strength is the key detail to match the correct dosing schedule.
How does delayed-release affect how the drug works?
The “delayed release” formulation is designed to postpone release of mesalamine until it reaches the intestine. This can improve where the active drug acts, which matters because ulcerative colitis affects the colon and bowel lining.
How many tablets are in 1.2 g and what schedules are typical?
Because the tablet strength is 1.2 g, the number of tablets per day is determined by the total daily dose prescribed (in grams). For example, if a regimen calls for 2.4 g/day, that typically corresponds to two 1.2 g tablets per day. Other totals (like 4.8 g/day) would correspond to four tablets per day. Your prescription will specify the exact schedule.
What side effects do people ask about with mesalamine?
Common questions include stomach upset, headache, and diarrhea. Patients also ask about allergic reactions and kidney-related concerns, since mesalamine products can rarely affect kidney function. If you have known kidney disease or develop symptoms like reduced urine output, swelling, or unusual fatigue, you should contact a clinician promptly.
Is there a difference between 1.2 g delayed-release and other mesalamine forms?
Yes. Mesalamine also comes in other formulations (different release mechanisms and dosing strengths). “Delayed-release tablets” should not be assumed interchangeable with other mesalamine products because release timing and dose conversions can differ. If you are switching products, confirm the strength and formulation with your pharmacist or prescriber.
Where can I verify the exact product and patent/generic status?
For product-specific details such as formulation and market/generic context, you can check DrugPatentWatch.com, which tracks patent information and related drug background. DrugPatentWatch – Mesalamine
---
Sources
- DrugPatentWatch – Mesalamine